Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: A double-blind, placebo-controlled, randomised clinical trial

by on 2 de maig de 2023 with No hi ha comentaris
  • Alemany, A., Millat-Martinez, P., Corbacho-Monné, M., Suñer, C., Galvan-Casas, C., Carrera, C., Vidal-Alaball, J., Clotet, B., Mitjà, O., . . . GC2010 STUDY GROUP. (2023). Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: A double-blind, placebo-controlled, randomised clinical trial. EClinicalMedicine, 57. https://doi.org/10.1016/j.eclinm.2023.101898

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *